[go: up one dir, main page]

DK2694538T3 - Terapeutiske og profylaktiske fremgangsmåder, anvendelser og sammensætninger omfattende anexin a5 - Google Patents

Terapeutiske og profylaktiske fremgangsmåder, anvendelser og sammensætninger omfattende anexin a5

Info

Publication number
DK2694538T3
DK2694538T3 DK12713969.9T DK12713969T DK2694538T3 DK 2694538 T3 DK2694538 T3 DK 2694538T3 DK 12713969 T DK12713969 T DK 12713969T DK 2694538 T3 DK2694538 T3 DK 2694538T3
Authority
DK
Denmark
Prior art keywords
anexin
therapeutic
applications
prophylactic procedures
comprehensive
Prior art date
Application number
DK12713969.9T
Other languages
English (en)
Inventor
Knut Pettersson
Original Assignee
Annexin Pharmaceuticals Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Annexin Pharmaceuticals Ab filed Critical Annexin Pharmaceuticals Ab
Application granted granted Critical
Publication of DK2694538T3 publication Critical patent/DK2694538T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4728—Calcium binding proteins, e.g. calmodulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
DK12713969.9T 2011-04-05 2012-04-05 Terapeutiske og profylaktiske fremgangsmåder, anvendelser og sammensætninger omfattende anexin a5 DK2694538T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161472002P 2011-04-05 2011-04-05
US201161472013P 2011-04-05 2011-04-05
PCT/EP2012/056370 WO2012136819A1 (en) 2011-04-05 2012-04-05 Therapeutic and prophylactic methods, uses and compositions comprising anexin a5

Publications (1)

Publication Number Publication Date
DK2694538T3 true DK2694538T3 (da) 2017-01-02

Family

ID=45953134

Family Applications (1)

Application Number Title Priority Date Filing Date
DK12713969.9T DK2694538T3 (da) 2011-04-05 2012-04-05 Terapeutiske og profylaktiske fremgangsmåder, anvendelser og sammensætninger omfattende anexin a5

Country Status (7)

Country Link
US (3) US20140037614A1 (da)
EP (1) EP2694538B1 (da)
DK (1) DK2694538T3 (da)
ES (1) ES2607066T3 (da)
HU (1) HUE030922T2 (da)
PL (1) PL2694538T3 (da)
WO (1) WO2012136819A1 (da)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10987313B2 (en) 2013-10-07 2021-04-27 Impax Laboratories, Llc Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
ES2823000T3 (es) 2013-10-07 2021-05-05 Impax Laboratories Llc Formulaciones muco-adhesivas de liberación controlada de levodopa y/o ésteres de levodopa y usos de las mismas
GB2542391A (en) 2015-09-17 2017-03-22 Annexin Pharmaceuticals Ab Process of manufacture
GB201702144D0 (en) * 2017-02-09 2017-03-29 Annexin Pharmaceuticals Ab Therapeutic compositions
US11357823B2 (en) * 2019-08-30 2022-06-14 Suzhou Yabao Pharmaceutical R&D Co., Ltd Method for treating cerebral stroke
JP2024501235A (ja) 2020-12-22 2024-01-11 アムニール ファーマスーティカルズ エルエルシー レボドパ投薬レジメン
US11986449B2 (en) 2020-12-22 2024-05-21 Amneal Pharmaceuticals Llc Levodopa dosing regimen
CN115245559A (zh) * 2021-04-25 2022-10-28 上海萨美细胞技术有限公司 一种用于治疗肺损伤的药物
CN117897399A (zh) 2021-06-14 2024-04-16 Inserm(法国国家健康医学研究院) 突变的膜联蛋白a5多肽及其在治疗目的中的用途
CA3189560A1 (en) * 2022-03-04 2023-09-04 Suzhou Yabao Pharmaceutical R&D Co., Ltd. Methods of treating a traumatic brain injury
CN118490808A (zh) * 2023-02-15 2024-08-16 上海萨美细胞技术有限公司 一种用于治疗骨质疏松症的药物
CN118001375A (zh) * 2023-04-12 2024-05-10 上海萨美细胞技术有限公司 一种用于难愈性创面修复的药物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7635676B2 (en) * 2001-02-21 2009-12-22 Alavita Pharmaccuticals, Inc. Modified annexin proteins and methods for their use in organ transplantation
EP1839670A3 (en) 2001-02-21 2009-11-11 Alavita Pharmaceuticals, Inc. Modified Annexin Proteins and their use against thrombosis
WO2005099744A1 (en) 2004-04-15 2005-10-27 Athera Biotechnologies Ab Annexin v for preventing atherothrombois and plaque rupture
EP2234631B1 (en) 2007-12-18 2012-09-12 Athera Biotechnologies AB Compounds and methods for the treatment of vascular disease
TR201909412T4 (tr) 2008-02-22 2019-07-22 Annexin Pharmaceuticals Ab Restenozun önlenmesi veya tedavisi için bileşikler ve yöntemler.

Also Published As

Publication number Publication date
PL2694538T3 (pl) 2017-04-28
ES2607066T3 (es) 2017-03-29
US20200179484A1 (en) 2020-06-11
HUE030922T2 (en) 2017-06-28
EP2694538A1 (en) 2014-02-12
WO2012136819A1 (en) 2012-10-11
EP2694538B1 (en) 2016-09-14
US20180015142A1 (en) 2018-01-18
US20140037614A1 (en) 2014-02-06

Similar Documents

Publication Publication Date Title
DK2694538T3 (da) Terapeutiske og profylaktiske fremgangsmåder, anvendelser og sammensætninger omfattende anexin a5
IL250824B (en) Certain amino-pyrimidines, their assemblies, and methods of using them
ME03766B (me) Određeni amino-pirimidini, njihove kompozicije, i metode njihove upotrebe
DK2729151T3 (da) Farmaceutisk sammensætning, fremgangsmåder til behandling og anvendelser deraf
DK3597644T3 (da) Kationiske aminlipider og anvendelser deraf
HUE038759T2 (hu) Terápiás nukleázkészítmények és eljárások
DK2872153T3 (da) Accellulære pro-tolerogene sammensætninger og fremgangsmåde til fremstilling heraf
DK3415157T3 (da) N-acyldipeptidderivater og anvendelser deraf
LT2704703T (lt) Transderminės ibuprofeno kompozicijos ir jų naudojimo būdai
DK3366143T3 (da) Probiotiske sammensætninger og fremgangsmåder
GB2501611B (en) Alpha-2-macroglobulin compositions and therapeutic uses
BR112014010290A2 (pt) composição farmacêutica, métodos, composições e usos
DK2745849T3 (da) Polydeoxyribonukleotidsammensætning og anvendelser deraf
SG10201913382YA (en) Topical compositions and methods of use
GB201113770D0 (en) Novel compositions and uses thereof
LT2680829T (lt) Kompozicijos ir būdai, skirti nechirurginiam ptozės gydymui
EP2663576A4 (en) NEW WNT COMPOSITIONS AND THERAPEUTIC APPLICATIONS OF SUCH COMPOSITIONS
DK2917181T3 (da) Heteroarylderivater og anvendelser deraf
DK2704744T3 (da) Komplementfaktor-b-analoger og anvendelser deraf
BR112014020677A2 (pt) composições de farinha de milho e métodos de produção
DK2661274T3 (da) Sammensætninger og fremgangsmåder med aloepolysaccharider
DK2854822T3 (da) Polysaccharidsammensætninger og fremgangsmåder til anvendelse
IL235262A0 (en) Polymorph preparations, methods for their preparation and uses
DK3210990T3 (da) Levoisovalerylspiramycin iii og præparater, fremstillingsfremgangsmåder og anvendelser deraf
PL2729021T3 (pl) Żelowa kompozycja